Oncology Peer Review On-The-Go: 1-on-1 with Dr. Xu Ji: Mental Health Among Cancer Survivors

Podcast

In the newest episode of Oncology Peer Review On-The-Go, CancerNetwork speaks with Xu Ji, PhD, MSPH, of the Winship Cancer Institute about her research on the topic of adult cancer survivorship and mental health.

In this episode of Oncology Peer Review On-The-Go, CancerNetwork speaks 1-on-1 with Xu Ji, PhD, MSPH, of the Winship Cancer Institute regarding her research entitled "Mental Health Among Nonelderly Adult Cancer Survivors: A National Estimate."

Subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
4 experts are featured in this series.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
4 experts are featured in this series.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content
The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

Osimertinib Combo Significantly Prolongs Survival in Advanced EGFR+ NSCLC

Russ Conroy
July 22nd 2025
Article

Investigators will present updated findings from the phase 3 FLAURA2 trial at a future medical meeting.

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

New Peritoneal Surface Malignancy Guidelines Aim to Improve Unity in Oncologists

Tim Cortese
July 21st 2025
Article

The new guidelines relied on trainees to bring new energy and ideas to advance the landscape of care for peritoneal surface malignancies.

EU approval of the agent is based on phase 2b ReNeu trial results, which met its primary end point of confirmed objective response rate in NF1-PN.

Mirdametinib Earns Conditional European Approval in Adult/Pediatric NF1-PN

Roman Fabbricatore
July 21st 2025
Article

EU approval of the agent is based on phase 2b ReNeu trial results, which met its primary end point of confirmed objective response rate in NF1-PN.